MARKET

ARQT

ARQT

Arcutis Biotherapeutics, Inc.
NASDAQ
9.85
+0.26
+2.71%
Opening 11:01 03/28 EDT
OPEN
9.67
PREV CLOSE
9.59
HIGH
9.91
LOW
9.64
VOLUME
463.04K
TURNOVER
0
52 WEEK HIGH
15.40
52 WEEK LOW
1.760
MARKET CAP
1.11B
P/E (TTM)
-2.6042
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ARQT last week (0318-0322)?
Weekly Report · 3d ago
Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
NASDAQ · 03/19 13:55
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)
TipRanks · 03/19 05:50
Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
NASDAQ · 03/18 13:55
Weekly Report: what happened at ARQT last week (0311-0315)?
Weekly Report · 03/18 09:15
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)
TipRanks · 03/13 06:30
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
U.S. Stocks were lower on Monday, with the Dow Jones index falling more than 150 points. Shares of EQT Corporation fell sharply after the company announced a merger agreement to acquire Equitrans Midstream. Ventyx Biosciences, Inc. Shares tumbled 18.5% to $8.09.
Benzinga · 03/11 14:37
Press Release: Arcutis Promotes Todd Tucker to Chief Human Resources Officer
Arcutis Biotherapeutics, Inc. Promotes Todd Tucker to senior vice president and Chief Human Resources Officer. Mr. Tucker has over 25 years' experience in human resources at pharmaceutical companies. Arcutis is a commercial-stage company focused on developing meaningful innovations in immuno-dermatology.
Dow Jones · 03/11 12:00
More
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.

Webull offers Arcutis Biotherapeutics Inc stock information, including NASDAQ: ARQT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARQT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARQT stock methods without spending real money on the virtual paper trading platform.